# Link Cell Therapies

> Link Cell Therapies develops experimental logic-gated CAR-T treatments for solid and hematologic cancers. Its lead candidate, LNK001, uses simultaneous recognition of CAIX and ENPP3 to target clear cell renal cell carcinoma while aiming to spare healthy tissue. Clinical dosing began in 2026.

- **Founded:** 2022
- **Headquarters:** South San Francisco, United States
- **Founders:** Robbie Majzner (Scientific co-founder and board member), Crystal Mackall (Scientific co-founder), Brian Slingerland (Co-founder and Executive Chair)
- **Products:** LINK platform, LNK001, Colorectal cancer program, ZAP, BOOST
- **Notable:** Foundational Nature paper published in March 2023., Kidney-cancer target discovery screened over 28 million potential pairs., LNK001 entered clinical dosing in 2026.

## Products & services

- **LINK platform** — Logic-gated intracellular network CAR technology; requires two antigens on the same target cell. Experimental.
- **LNK001** — Autologous CAIX/ENPP3 AND-gated CAR-T candidate in Phase 1 for advanced clear cell renal cell carcinoma.
- **Colorectal cancer program** — Development program with first-in-human studies planned for 2027; target pair not disclosed in the announcement.
- **ZAP** — Platform described in 2023 as engaging ZAP-70 signaling to reduce T-cell exhaustion; current standalone status unverified.
- **BOOST** — Platform described in 2023 as amplifying CAR and TCR signaling against low-antigen targets; current standalone status unverified.

## Achievements

- Foundational Nature paper published in March 2023.
- Kidney-cancer target discovery screened over 28 million potential pairs.
- LNK001 entered clinical dosing in 2026.

## Latest updates

- **2026-09** — Clinical dosing initiated; Jie D’Elia appointed CEO; Friedrich Graf Finckenstein announced as CMO; Series A expanded to USD 90 million.
- **2026-01** — Resources index dates the Johnson & Johnson collaboration January 9, 2026; release body inconsistently says 2025.
- **2025-12** — Stealth launch announced with USD 60 million Series A and USD 92 million cumulative funding.

## Links

- Website: https://linkcelltx.com/
- LinkedIn: https://www.linkedin.com/company/linkcelltx/

---

Profile page: https://yespress.io/link-cell-therapies
Published by YesPress — https://yespress.io
Last updated: 2026-10-01